Literature DB >> 9708802

Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.

J R Gebhard1, C M Perry, S Harkins, T Lane, I Mena, V C Asensio, I L Campbell, J L Whitton.   

Abstract

Viral myocarditis is remarkably common, being detected in approximately 1% of unselected asymptomatic individuals. Many cases are attributable to enteroviral infection, and in particular to coxsackievirus B3. The underlying pathogenesis is controversial, but most studies admit the important immunopathological role of infiltrating CD8+ (cytotoxic) T lymphocytes (CTLs). We have previously shown that CTLs play conflicting roles in coxsackievirus B (CVB) myocarditis; they assist in controlling virus replication, but also are instrumental in causing the extensive inflammatory disease, which often results in severe myocardial scarring. A role for perforin, the major CTL cytolytic protein, in CVB myocarditis has been suggested, but never proven. In the present study we use perforin knockout (PKO) mice to show that perforin plays a major role in CVB infection; in broad terms, perforin is important in immunopathology, but not in CVB clearance. For example, PKO mice are better able to withstand a normally lethal dose of CVB (100% survival of PKO mice compared with 90% death in +/+ littermates). In addition, PKO mice given a nonlethal dose of CVB develop only a mild myocarditis, whereas their perforin+ littermates have extensive myocardial lesions. The myocarditis in PKO mice resolves more quickly, and these mice show minimal histological sequelae; in contrast, late in disease the perforin+ mice develop severe myocardial fibrosis. PKO mice, despite lacking this major CTL effector function, can control the infection and eradicate the virus; growth kinetics and peak CVB titers are indistinguishable in PKO and perforin+ mice. Therefore, the immunopathological and antiviral effects of CTLs can be uncoupled by ablation of perforin; this offers a promising target for therapy of myocarditis. Furthermore, we evaluate the possible roles of apoptosis, and of chemokine expression, in CVB infection. In perforin+ mice, apoptotic cells are detected within the inflammatory infiltrate, whereas in their PKO counterparts, apoptotic myocyte nuclei are seen. Chemokine expression in both PKO and perforin+ mice precedes and parallels the course of myocarditis. Several chemokines are detectable earlier in PKO mice than in perforin+ mice, but PKO mice show reduced peak levels, and chemokine expression decays sooner. In particular, MIP-1alpha expression is barely detectable at any time point in PKO mice, but it is readily identified in perforin+ animals, peaking just before the time of maximal myocarditis; this is particularly interesting, given that MIP-1alpha knockout mice are resistant to CVB myocarditis, but remain able to control viral infection. Thus, the chemokine pathway offers a second route of intervention to diminish myocarditis and its sequelae, while permitting the host to eradicate the virus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708802      PMCID: PMC1852975          DOI: 10.1016/S0002-9440(10)65585-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  69 in total

1.  Incidence of myocarditis. A 10-year autopsy study from Malmö, Sweden.

Authors:  M B Gravanis; N H Sternby
Journal:  Arch Pathol Lab Med       Date:  1991-04       Impact factor: 5.534

2.  The Registry of the International Society for Heart Transplantation: sixth official report--1989.

Authors:  C F Heck; S J Shumway; M P Kaye
Journal:  J Heart Transplant       Date:  1989 Jul-Aug

Review 3.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

4.  Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas.

Authors:  R Khatib; J L Chason; B K Silberberg; A M Lerner
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

5.  Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice.

Authors:  L J Wolfgram; K W Beisel; A Herskowitz; N R Rose
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

6.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

7.  The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.

Authors:  Y Hiraoka; C Kishimoto; M Kurokawa; H Ochiai; S Sasayama
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

8.  Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.

Authors:  C Kishimoto; H Takada; Y Kuroki; I Matsushita; Y Hiraoka; M Kurokawa; H Ochiai; S Sasayama
Journal:  Cardiovasc Res       Date:  1993-02       Impact factor: 10.787

9.  Requirement of MIP-1 alpha for an inflammatory response to viral infection.

Authors:  D N Cook; M A Beck; T M Coffman; S L Kirby; J F Sheridan; I B Pragnell; O Smithies
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

Review 10.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01
View more
  53 in total

1.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Highly active antiretroviral therapy and beta-chemokines.

Authors:  B Brichacek; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

4.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

5.  Analysis of translational initiation in coxsackievirus B3 suggests an alternative explanation for the high frequency of R+4 in the eukaryotic consensus motif.

Authors:  Stephanie Harkins; Christopher T Cornell; J Lindsay Whitton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

7.  Pancreatic acinar cell-specific autophagy disruption reduces coxsackievirus replication and pathogenesis in vivo.

Authors:  Mehrdad Alirezaei; Claudia T Flynn; Malcolm R Wood; J Lindsay Whitton
Journal:  Cell Host Microbe       Date:  2012-03-15       Impact factor: 21.023

8.  Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes.

Authors:  Gudrun Szalay; Silke Meiners; Antje Voigt; Jörg Lauber; Christian Spieth; Nora Speer; Martina Sauter; Ulrike Kuckelkorn; Andreas Zell; Karin Klingel; Karl Stangl; Reinhard Kandolf
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice.

Authors:  Carola Leipner; Katja Grün; Ilka Schneider; Brigitte Glück; Holger H Sigusch; Axel Stelzner
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

10.  Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis.

Authors:  Jimena Cuenca; Paloma Martín-Sanz; Alberto M Alvarez-Barrientos; Lisardo Boscá; Nora Goren
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.